Arrowhead Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Ste...
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals announces positive Phase 3 PALISADE study results for plozasiran in patients with familial chylomicronemia syndrome (FCS), showing significant reductions in triglycerides and risk of acute pancreatitis, with plans to file a New Drug Application with the FDA by year-end 2024.
Related Clinical Trials:
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of ...
JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.
© Copyright 2024. All Rights Reserved by MedPath